Number of the records: 1  

Alzheimer’s Disease II

  1. Title statementAlzheimer’s Disease II [electronic resource] / edited by Michael S. Wolfe.
    PublicationCham : Springer International Publishing : Imprint: Springer, 2017.
    Phys.des.VII, 202 p. 90 illus., 33 illus. in color. online resource.
    ISBN9783319594606
    EditionTopics in Medicinal Chemistry, ISSN 1862-2461 ; 24
    ContentsTargets and Strategies Toward the Development of Alzheimer Therapeutics -- The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease -- γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease -- Inhibitors of Tau-Phosphorylating Kinases -- Microtubule-Stabilizing Agents for Alzheimer’s and Other Tauopathies -- PET Imaging Agents for Alzheimer’s Disease.
    Notes to AvailabilityPřístup pouze pro oprávněné uživatele
    Another responsib. Wolfe, Michael S.
    Another responsib. SpringerLink (Online service)
    Subj. Headings Chemistry. * Neurosciences. * Pharmaceutical technology. * Medicinal chemistry. * Proteins.
    Form, Genre elektronické knihy electronic books
    CountryNěmecko
    Languageangličtina
    Document kindElectronic books
    URLPlný text pro studenty a zaměstnance UPOL
    book

    book


    Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors .

    Targets and Strategies Toward the Development of Alzheimer Therapeutics -- The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease -- γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease -- Inhibitors of Tau-Phosphorylating Kinases -- Microtubule-Stabilizing Agents for Alzheimer’s and Other Tauopathies -- PET Imaging Agents for Alzheimer’s Disease.

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.